Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice

Antiviral Research

Volumn 86, Issue 2, 2010, Pages 180-187

  Prabakaran, Mookkan ^a   Madhan, Selvaraj ^a   Prabhu, Nayana ^a   Geng, Grace Yuhong ^b   New, Roger ^c   Kwang, Jimmy ^a,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Cellbiotech Co Ltd   (South Korea)

^c Proxima Concepts   (United Kingdom)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Baculovirus; H5N1; Oral; Reverse micelle; Surface display

Indexed keywords

CHOLERA TOXIN B SUBUNIT; HEMAGGLUTININ; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; PHOSPHATIDYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CONTROLLED STUDY; DRUG SAFETY; ENCAPSULATION; FEMALE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE MICELLE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BACULOVIRIDAE; CHOLERA TOXIN; CROSS REACTIONS; FEMALE; GENETIC VECTORS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MUCOUS MEMBRANE; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS;

MUS;

EID: 77951297002     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.02.315     Document Type: Article

References (43)

1. Amorij J.P., Westra T.A., Hinrichs W.L., Huckriede A., Frijlink H.W. Towards an oral influenza vaccine: comparison between intragastric and intracolonic delivery of influenza subunit vaccine in a murine model. Vaccine 2007, 26:67-76.
2. Atmar R.L., Keitel W.A., Cate T.R., Munoz F.M., Ruben F., Couch R.B. A dose response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine 2007, 25:5367-5373.
3. Barackman J.D., Ott G., Pine S., O'Hagan D.T. Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization. Clin. Diagn. Lab. Immunol. 2001, 8:652-657.
4. Bender B.S., Rowe C.A., Taylor S.F., Wyatt L.S., Moss B., Small P.A. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J. Virol. 1996, 70:6418-6424.
5. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., Kumar N.M., Pushko P., Smith G., Tumpey T.M., Ross Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008, 3:e1501.
6. Bright R.A., Shay D.K., Shu B., Cox N.J., Klimov A.I. Adamantane resistance among influenza A (H3N2) viruses isolated early during the 2005-2006 influenza season in the United states. JAMA 2006, 295:891-894.
7. Centers for Disease Control and Prevention (CDCP). 2009. Update: swine influenza A (H1N1) infections-California and Texas, April 2009. MMWR Morb. Mortal Wkly Rep. 58, 435-437.
8. Centers for Disease Control and Prevention (CDCP). 2004. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 53, 1-40.
9. Conacher M., Alexander J., Brewer J.M. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine 2001, 19:2965-2974.
10. Couch R.B., Winokur P., Brady R., Belshe R., Chen W.H., Cate T.R., Sigurdartoddir B., Hoeper A., Graham I.L., Edelman R., He F., Nino D., Capellan J., Ruben F.L. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007, 25:7656-7663.
11. Cox R.J., Brokstad K.A., Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 2004, 59:1-15.
12. de Jong M.D., Hien T.T. Avian influenza A (H5N1)-Review. J. Clin. Virol. 2006, 35:2-13.
13. Domingos M.O., Lewis D.J., Jansen T., Zimmerman D.H., Williamson E.D., New R.R.C. A New Oil-Based Antigen Delivery Formulation for both Oral and Parenteral Vaccination. Open Drug Del. J. 2008, 2:52-60.
14. Gallagher S., Winston S.E., Fuller S.A., Hurrell J.G.R. Immunoblotting and immunodetection. Current Protocols in Molecular Biology 2004, John Wiley & Sons, Inc., Newcastle, United Kingdom, pp. 10.8.1-10.8.24. F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore (Eds.).
15. Gao W., Soloff A.C., Lu X., Montecalvo A., Nguyen D.C., Matsuoka Y., Robbins P.D., Swayne D.E., Donis R.O., Katz J.M., Barratt-Boyes S.M., Gambotto A. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J. Virol. 2006, 80:1959-1964.
16. Gao H., Wang Y., Li N., Peng W.P., Sun Y., Tong G.Z., Qiu H.J. Efficient gene delivery into mammalian cells mediated by a recombinant baculovirus containing a whispovirus ie1 promoter, a novel shuttle promoter between insect cells and mammalian cells. J. Biotechnol. 2007, 131:138-143.
17. He F., Madhan S., Kwang J. Baculovirus vector as a delivery vehicle for influenza vaccines. Expert. Rev. Vaccines 2009, 8:455-467.
18. Ito R., Ozaki Y.A., Yoshikawa T., Hasegawa H., Sato Y., Suzuki Y., Inoue R., Morishima T., Kondo N., Sata T., Kurata T., Tamura S. Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. Vaccine 2003, 23:2362-2371.
19. Jansen T., Hofmans M.P., Theelen M.J., Manders F., Schijns V.E. Structure- and oil type-based efficacy of emulsion adjuvants. Vaccine 2006, 24:5400-5405.
20. Kelsall B.L., Strober W. Distinct populations of dendritic cells are present in the subepithelial dome and T cell regions of murine Peyer's patches. J. Exp. Med. 1996, 183:237-247.
21. Kuroda K., Geyer H., Geyer R., Doerfler W., Klenk H.D. The oligosaccharides of influenza virus hemagglutinin expressed in insect cells by a baculovirus vector. Virology 1990, 174:418-429.
22. Liew F.Y., Russell S.M., Appleyard G., Brand C.M., Beale J. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T-cell reactivity. Eur. J. Immunol. 1984, 14:350-356.
23. Mann J.F., Ferro V.A., Mullen A.B., Tetley L., Mullen M., Carter K.C., Alexander J., Stimson W.H. Optimization of a lipid based oral delivery system containing A/Panama influenza hemagglutinin. Vaccine 2004, 22:2425-2429.
24. Neutra M.R., Mantis N.J., Kraehenbuhl J.P. Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat. Immunol. 2001, 2:1004-1009.
25. NIH (National Institutes of Health, U.S.); CDCP (Centers for Disease Control and Prevention, U.S.), 1999. Biosafety in microbiological and biomedical laboratories, 4th ed. U.S. Dept. of Health and Human Services Public Health Service Centers for Disease Control and Prevention; National Institutes of Health. For sale by the Supt. of Docs. U.S. G.P.O., Washington, D.C.
26. Ogra P.L., Faden H., Welliver R.C. Vaccination Strategies for Mucosal Immune Responses. Clin. Microbiol. Rev. 2001, 14:430-445.
27. O'Reilly D.R., Miller L.K., Luckow V.A. Baculovirus 542 expression vectors. A Laboratory Manual 1992, vol. 543:60-61. Company, New York.
28. Pang G.T., Clancy R., O'Reilly S.E., Cripps A.W. A novel particulate influenza vaccine induces long-term and broad-based immunity in mice after oral immunization. J. Virol. 1992, 66:1162-1170.
29. Pauletti G.M., Gangwar S., Knipp G.T., Nerurkar M.M., Okumu F.W., Tamura K., Siahaan T.J., Borchardt R.T. Structural requirements for intestinal absorption of peptide drugs. J. Con. Rel. 1996, 41:3-17.
30. Peralta A., Molinari P., Conte-Grand D., Calamante G., Taboga O. A chimeric baculovirus displaying bovine herpesvirus-1 (BHV-1) glycoprotein D on its surface and their immunological properties. Appl. Microbiol. Biotechnol. 2007, 75:407-414.
31. Prabakaran M., Velumani S., He F., Karuppannan A.K., Geng G.Y., Yin L.K., Kwang J. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Virology 2008, 380:412-420.
32. Prabakaran M., Ho H.T., Prabhu N., Velumani S., Szyporta M., He F., Chan K.P., Chen L.M., Matsuoka Y., Donis R.O., Kwang J. Development of epitope-blocking ELISA for universal detection of antibodies to human H5N1 influenza viruses. PLoS ONE 2009, 4:e4566.
33. Ruat C., Caillet C., Bidaut A., Simon J., Osterhaus A.D. Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement. J. Virol. 2008, 82:2565-2569.
34. Rueda P., Fominaya J., Langeveld J.P., Bruschke C., Vela C., Casal J.I. Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles. Vaccine 2000, 19:726-734.
35. Shahiwala A., Amiji M.M. Enhanced mucosal and systemic immune response with squalane oil-containing multiple emulsions upon intranasal and oral administration in mice. J. Drug Target 2008, 16:302-310.
36. Takase H., Murakami Y., Endo A., Ikeuchi T. Antibody responses and protection in mice immunized orally against influenza virus. Vaccine 1996, 14:1651-1656.
37. Tamura S., Yamanaka A., Shimohara M., Tomita T., Komase K., Tsuda Y., Suzuki Y., Nagamine T., Kawahara K., Danbara H., et al. Synergistic action of cholera toxin B subunit (and Escherichia coli heatlabile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine 1994, 12:419-426.
38. Tani H., Limn C.K., Yap C.C., Onishi M., Nozaki M., Nishimune Y., Okahashi N., Kitagawa Y., Watanabe R., Mochizuki R., Moriishi K., Matsuura Y. In vitro and in vivo gene delivery by recombinant baculoviruses. J. Virol. 2003, 77:9799-9808.
39. Treanor J.J., Schiff G.M., Hayden F.G., Brady R.C., Hay C.M., Meyer A.L., Holden-Wiltse J., Liang H., Gilbert A., Cox M. Safety and immunogenicity of a baculovirus expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 2007, 297:1577-1582.
40. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., Wolff M., Rabinovich G., Blackwelder W., Katz J.M. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001, 19:1732-1737.
41. Webster R.G., Kawaoka Y., Taylor J., Weinberg R., Paoletti E. Efficacy of nucleoprotein and hemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine 1991, 9:303-308.
42. World Health Organization (WHO) Evolution of H5N1 avian influenza viruses in Asia. Emerg. Infect. Dis. 2005, 11:1515-1521.
43. Wood J.M., Schild G.C., Newman R.W., Seagroatt V. Application of an improved single-radial-immunodiffusion technique for the assay of haemagglutinin antigen content of whole virus and subunit influenza vaccines. Dev. Biol. Stand. 1977, 39:193-200.